Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
IPO Year:
Exchange: NASDAQ
Website: heliusmedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2021 | Outperform → Market Perform | Noble Capital Markets |
8-K - Solana Co (0001610853) (Filer)
S-3ASR - Solana Co (0001610853) (Filer)
8-K - Solana Co (0001610853) (Filer)
DEF 14A - Solana Co (0001610853) (Filer)
PRE 14A - Solana Co (0001610853) (Filer)
SCHEDULE 13G - Solana Co (0001610853) (Subject)
8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)
8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)
8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)
S-3ASR - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
Fastest customizable press release news feed in the world
NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ:HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment for Solana Company (NASDAQ:HSDT). We have made the deliberate choice to move forward with our scheduled registration for resale of the shares purchased by investors in the recent private placement rather than delay it. Whereas some of our peers have decided to postpone it at the first sign of market volatility, we want to explain why we made this decision and why we feel
Solana Company (NASDAQ:HSDT) ("HSDT" or "the Company"), formerly known as Helius Medical Technologies, Inc., today announced it has selected BitGo, the digital asset infrastructure company, to serve as a custodian for the Company's holdings of SOL, the native asset of the Solana Network. The partnership supports Solana Company's digital asset treasury strategy as it continues to build its position in SOL. "Our collaboration with BitGo reinforces HSDT's commitment to advance its mission of building a strong, transparent digital asset treasury," said Joseph Chee, Executive Chairman of HSDT and Chairman of Summer Capital. "As we build our SOL treasury, we aim to uphold best practices that al
NEWTOWN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Solana Company, (NASDAQ:HSDT, )), formerly Helius Medical Technologies, Inc., today announced it has entered into agreements with Coinbase, BitGo and Anchorage Digital to serve as custodians as it continues amassing SOL, the native asset of the Solana Network, as part of its digital assets treasury strategy. "As HSDT continues to operate as the preeminent SOL-focused treasury, establishing relationships with leading custodians like Coinbase, BitGo, and Anchorage Digital reflects our disciplined and scalable approach to maximizing shareholder value," said Cosmo Jiang, General Partner at Pantera Capital and Board Observer at HSDT. "This custod
NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its continued acquisition of Solana ("SOL") tokens as part of its digital asset treasury strategy. The Company now holds over 2.2 million SOL. The Company also holds in excess of $15 million of cash, which it intends to use to further the digital asset treasury strategy. The Company's combined Solana holdings (at $232.50 per SOL as of October 6th at 12:00AM ET) and cash holdings exceed $525mm of value, exceeding the amount of gross proceeds from the initial private placement offering that closed on September 18th. These SOL purchases underscore HSDT's commitment to
HSDT Solana Company's Mission is to maximize SOL per share on one of the most commercially viable blockchains for consumer applications while delivering consistent on-chain yield for investors HSDT enters into agreement with the Solana Foundation to establish its collaboration and commit to joint initiatives This signifies HSDT's commitment to building a long-lasting institution that accelerates the growth of Solana and being a powerful advocate for Solana's development alongside the independent Solana Foundation and Solana Lab NEWTOWN, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) ("HSDT" or the "Company") announced that, following receipt of
NEWTOWN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), today announced the filing of its U.S. Food and Drug Administration (FDA) 510(k) submission for the PoNS (Portable Neuromodulation Stimulator) device label expansion seeking an indication for gait and balance deficit in patients with chronic stroke symptoms. The submission was made with data generated in its Stroke Registrational Program (SRP) and was filed under its current FDA Breakthrough Device Designation. All statistical analyses for the Functional Gait Assessment (FGA) primary endpoint demonstrated PoNS superior effectiveness in improving gait deficit by achieving a clinically meani
NEWTOWN, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its first acquisition of Solana ("SOL") tokens as part of its digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana Blockchain. The Company now holds over 760,190 SOL, with an average cost basis of $231. The Company also holds in excess of $335 million of cash, which it intends to use to further the digital asset treasury strategy. These SOL purchases underscore HSDT's commitment to the Company's Solana treasury strategy and long-term confidence in the Solana ecosystem. "We are excited to embark on ou
Preeminent SOL-backed treasury vehicle - with potential to raise over $1.25 billion aggregate gross proceeds - unlocks capital markets to accelerate Solana's growth The financing drew participation from leading investors across traditional finance and crypto, including Big Brain Holdings, Avenir, SinoHope, FalconX, Arrington Capital, Animoca Brands, Aspen Digital, Borderless, Laser Digital, HashKey Capital, and Republic Digital NEWTOWN, Pa., Sept. 18, 2025 /PRNewswire/ -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company") today announced that it has closed its previously announced private placement offering (the "Offering") of common stock and stapled warrants to pur
Preeminent SOL-backed treasury vehicle - with potential to deliver over $1.25 billion - unlocks capital markets to accelerate Solana's growth The offering was led by institutional and crypto-native investors such as Pantera Capital, Summer Capital, and other prominent backers including Big Brain Holdings, Avenir, SinoHope, FalconX, Arrington Capital, Animoca Brands, Aspen Digital, Borderless, Laser Digital, HashKey Capital, and Republic DigitalThe SOL treasury strategy will be led by incoming Director and Executive Chairman Joseph Chee (Founder and Chairman of Summer Capital and Former Head of Investment Banking, Asia at UBS), Board Observer Cosmo Jiang (General Partner at Pantera Capital)
NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under the current Breakthrough Device Designation. The key primary outcomes from the SRP indicate that: A double-blind randomized clinical trial met the primary endpoint of demonstrating statistically significant greater impr
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform
Noble Capital Markets initiated coverage of Helius Medical with a rating of Outperform and set a new price target of $20.00
LADENBURG THALM/SH SH initiated coverage of Helius Medical Technologies with a rating of Buy
Live finance-specific insights
NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator (PoNS) device and announced plans to host a business update call today at 9:00am ET. "We disagree with the proposed pricing for the PoNS Mouthpiece and are disappointed CMS has once again mapped the Controller pricing to a code for fundamentally different technology," said Dane Andreeff, Helius' President and Chief Executive Officer. "I
NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date:Monday, Augus
NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2024 financial results on Monday, May 13, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date: Monday, May 13, 2
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2023. Fourth Quarter and Recent Business Updates Secured Healthcare Common Procedure Coding System ("HCPCS") Level II codes for the Portable Neuromodulation Stimulator ("PoNS®") mouthpiece and controller from the Centers for Medicare & Medicaid Services ("CMS"), representing a significant step toward reimbursement.Further expanded th
NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, March 28, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS
-- Cash runway extended into Q2 2024 ---- Company to host call at 4:30pm today -- NEWTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended September 30, 2023. Third Quarter and Recent Business Updates Q3 2023 revenue of $143 thousand, compared to $196 thousand in Q3 2022, the decrease due to the expiration of the Patient Therapy Access Program ("PTAP") on June 30, 2023.Operating cash burn of $2.5 million in Q3 2023, a decrease of $1.4 million compared to Q3 2
-- Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023 -- -- Expects to report approximately $7.0 million in cash, cash equivalents and proceeds receivable from warrant exercises, extending cash runway into Q2 2024 ---- Expects to report cash used in operating activities for the first nine months of 2023 ranging from $8.3 - $8.4 million, and for Q3 $2.4 - $2.5 million, reflecting continued focus on cash management -- NEWTOWN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurote
-- Total Q2 revenue up 115% over prior year; 131% over Q1 2023 -- -- Company to host call at 4:30pm today -- NEWTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended June 30, 2023. Second Quarter and Recent Business Updates Q2 2023 revenue of $256 thousand, compared to $119 thousand in Q2 2022, an increase of 115%; up $145 thousand compared to Q1 2023, or 131%. Operating cash burn of $2.7 million in Q2 2023 decreased by $0.9 million compared to Q2 2022. Exp
NEWTOWN, Pa., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2023 financial results on Thursday, August 10, 2023, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date:Thursday, A
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended March 31, 2023. First Quarter and Recent Business Updates Q1 2023 revenue of $111 thousand, compared to $190 thousand in Q1 2022, the decrease due to revenue of $120 thousand recognized in the prior year quarter resulting from a one-time delivery of Portable Neuromodulation Stimulator (PoNS®) systems under our previous Canadian distribution agr
This live feed shows all institutional transactions in real time.
SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)
SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)
SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)
SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)
SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)
SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)
SC 13D/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)
SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)
SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)
SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)
Live Leadership Updates
NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ:HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment for Solana Company (NASDAQ:HSDT). We have made the deliberate choice to move forward with our scheduled registration for resale of the shares purchased by investors in the recent private placement rather than delay it. Whereas some of our peers have decided to postpone it at the first sign of market volatility, we want to explain why we made this decision and why we feel
-Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major
NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator (PoNS®) device for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. Deborah Backus, PT, Ph.D., FACRM – Vice President of Research and Innovation at Atlanta's Shepherd Center, one of six sit
NEWTOWN, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Paul Buckman to its Board of Directors, effective September 10, 2021. Mr. Buckman will serve as Chair of the Company's Audit Committee and as a member of its Compensation and Nominating & Governance Committees. "Paul is a highly accomplished executive with more than 30 years of experience in the medical device sector, including senior leadership positions at some of the most well-regarded companies in the industry," said Blane Walter, Chairman of Helius' Board of Directors. "I
Columbus, Ohio, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Better For You Wellness, Inc., formerly known as Fast Track Solutions, Inc., (OTC:FTRK) ("Better For You Wellness" or the "Company"), an Ohio-based blank check company, is pleased to announce that it has appointed five independent non-executive directors to its Board of Directors including Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD (the "New Directors"). All five New Directors have been appointed for initial terms of 2 years, and Better For You Wellness, Inc.'s seven member Board of Directors is now composed of a majority of Independent Directors demonstrating the Company's focus on governance
NEWTOWN, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Antonella Favit-Van Pelt, M.D., Ph.D. to the position of Chief Medical Officer. "I am very pleased to welcome Dr. Favit-Van Pelt to Helius, who joins our team with a clinical and academic background in Neurology, as well as 20 years of experience advising and leading medical programs for healthcare companies – including both large, globally-diversified corporations and smaller, earlier-stage companies," said Helius CEO, Dane Andreeff. "I look forward to her future cont
NEWTOWN, Pa., June 15, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced that Dane C. Andreeff and Jeffrey S. Mathiesen have been appointed to the respective positions of President and Chief Executive Officer and Chief Financial Officer, effective June 14, 2021. Joyce LaViscount will continue to serve as the Company's Chief Operating Officer. Mr. Andreeff has served as Helius' Interim President and Chief Executive Officer since August 2020 and as a member of the Company's Board of Directors since August 2017. Mr. Mathiesen served as a member of Helius' Board
NEWTOWN, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Frederick Fantazzia to the position of Vice President of Sales & Marketing, North America, effective June 1, 2021. "Fred is a dynamic leader with 16 years of sales and marketing experience in the field of neuromodulation, and a specific focus on developing the market for new neuromodulation technologies by building and leading high-quality sales team to raise awareness and facilitate commercial adoption," said Dane Andreeff, Interim President and Chief Executive Office
NEWTOWN, Pa., March 17, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the appointment of Sherrie Perkins, effective March 15, 2021. “Ms. Perkins’ career history includes over 20 years of experience in the healthcare industry, including significant experience advising neuromodulation companies on their commercial and marketing activities,” said Blane Walter, Chairman of Helius’ Board of Directors. “We are pleased to expand our Board of Directors with the appointment of Ms. Perkins and look forward to leveraging her expertise and strategic insight as Heli